Over the past several decades,
Taiho Oncology has continued to produce Successful Anticancer Treatments.

First came the launch of the anticancer agent Futraful (tegafur) in 1974. This led to Futraful E, the first oral anticancer agent, in 1981. With the obvious patient benefits of an oral anticancer regimen having been established, our zealous oncology team sought to discover additional treatments that focused on improving safety while increasing efficacy. These initiatives led to the launch of UFT (tegafur/uracil) in 1984. UFT demonstrated significant efficacy in a wide variety of cancers.

Soon after, Taiho Oncology discovered gimeracil, which proved to work even better than uracil at prolonging the plasma concentration for 5-FU. Gimeracil and oteracil potassium were then combined with Futraful to create TS-1. TS-1 (tegafur/oteracil/gimericil) was launched in 1999 and quickly became the standard of treatment for gastric cancer in Japan.

The proven track record of our past has brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach to continuously leverage expertise in antimetabolite therapies while also combining them with molecular targeted agents has uncovered a wide range of promising treatments for the future.

Product Pipleline (Clinical Development)

IND Code Dosage Form Indications Development Locations Development StagePhase I Phase II Phase III Filed
+S-1 Oral Gastric cancer US • • •  
Oral Uteralcervical cancer Japan, Asia • • •  
Oral Hepatocellular carcinoma Japan • • •  
Oral Renal cell carcinoma Japan • •    
XS-1 is an oral antimetabolite consisting of FT, CDHP, and oxonic acid. FT is a prodrug of 5-FU, CDHP enhances efficacy by inhibiting degradation of 5-FU, and oxonic acid reduces digestive tract-related side effects.
+ABI-007 Injection NSCLC Japan • • • •
Injection Gastric cancer Japan • • • •
XABI-007 is a nanoparticle formulation of paclitaxel.
+OVF Oral Cancer pain Japan • • •  
XOVF is a transmucosal fentanyl tablet for the treatment of breakthrough cancer pain.
+TSU-68 Oral Hepatocellular carcinoma Japan, Asia • • •  
Oral Gastric cancer Japan • • •  
Oral Colorectal cancer Asia • •    
XTSU-68 is a low-molecular-weight anti-angiogenetic agent that inhibits receptor tyrosine kinase.
+TAS-102 Oral Colorectal cancer Japan, US, EU • • •  
XTAS-102 is a novel combination antitumor agent, consisting of triflerothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI). FTD induces DNA dysfunction through efficient incorporation into DNA, which leads to the inhibition of tumor growth. The TPI prevents degradation of FTD.
+TAS-106 Injection Solid cancer US • • •  
XTAS-106 is an antitumor ribonucleoside that inhibits RNA polymerase.
+ET-743 Injection Malignant soft tissue tumors Japan •      
XET-743 is a novel marine-derived antitumor agent isolated from the colonial tunicate Ecteinascidia turbinate. The drug binds to the minor groove of the DNA and induces apoptosis.
+TAS-114 Oral Solid tumors Japan, US, EU •      
XTAS-114 is a nucleic acid-metabolizing enzyme inhibitor that intensifies the effects of 5-FU-based (pyrimidine fluoride) anticancer drugs.
+TAS-115 Oral Solid tumors Japan •      
XTAS-115 is a low-molecular-weight receptor tyrosine kinase inhibitor targeting MET and VEGFRs.